Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Comparison Table: Best Peptides for Cortisol Reduction

Thymalin T-cell modulation, cytokine regulation Reduces inflammation-driven cortisol demand through immune normalization Russian gerontology studies; aged rodent models; no randomized human cortisol trials 5–10mg subcutaneous, 2–3×/week Strongest rationale for

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Thymalin
  • T-cell modulation, cytokine regulation
  • Reduces inflammation-driven cortisol demand through immune normalization
  • Russian gerontology studies; aged rodent models; no randomized human cortisol trials
  • 5–10mg subcutaneous, 2–3×/week
  • Strongest rationale for immune-mediated cortisol modulation; human cortisol data limited to observational immune studies
  • P21
  • CNTF-mediated hippocampal neurogenesis
  • Restores HPA negative feedback by increasing glucocorticoid receptor density
  • Rodent stress models; no human cortisol endpoints published
  • 5mg subcutaneous daily
  • Mechanistically sound for chronic stress; no direct human cortisol measurement data
  • Dihexa
  • HGF/c-Met amplification, synaptic repair
  • Reverses cortisol-induced dendritic atrophy in hippocampus and cortex
  • Alzheimer's preclinical models; synaptic plasticity studies; cortisol not measured as endpoint
  • 1–5mg oral or subcutaneous daily
  • Indirect cortisol relevance through neuroprotection; cortisol reduction is speculative extrapolation
  • Cerebrolysin
  • Neurotrophic peptide mixture
  • Supports neuroplasticity in stress-damaged regions
  • Clinical stroke and TBI studies; cortisol not primary endpoint
  • 5–10mL IV infusion
  • Used clinically for neurological recovery; cortisol link is tertiary to neuroprotection
  • KPV
  • Anti-inflammatory tripeptide
  • Reduces systemic inflammation and may lower immune-driven cortisol demand
  • In vitro anti-inflammatory studies; no cortisol-specific trials
  • 500mcg–2mg subcutaneous
  • Anti-inflammatory mechanism plausible for secondary cortisol effects; no direct evidence